全文获取类型
收费全文 | 37206篇 |
免费 | 2622篇 |
国内免费 | 167篇 |
专业分类
耳鼻咽喉 | 286篇 |
儿科学 | 1117篇 |
妇产科学 | 732篇 |
基础医学 | 4652篇 |
口腔科学 | 647篇 |
临床医学 | 3583篇 |
内科学 | 8400篇 |
皮肤病学 | 566篇 |
神经病学 | 3863篇 |
特种医学 | 1138篇 |
外国民族医学 | 1篇 |
外科学 | 5215篇 |
综合类 | 536篇 |
一般理论 | 30篇 |
预防医学 | 3085篇 |
眼科学 | 742篇 |
药学 | 2636篇 |
1篇 | |
中国医学 | 54篇 |
肿瘤学 | 2711篇 |
出版年
2023年 | 234篇 |
2022年 | 350篇 |
2021年 | 712篇 |
2020年 | 478篇 |
2019年 | 704篇 |
2018年 | 814篇 |
2017年 | 625篇 |
2016年 | 676篇 |
2015年 | 818篇 |
2014年 | 1159篇 |
2013年 | 1629篇 |
2012年 | 2438篇 |
2011年 | 2717篇 |
2010年 | 1507篇 |
2009年 | 1393篇 |
2008年 | 2293篇 |
2007年 | 2599篇 |
2006年 | 2459篇 |
2005年 | 2549篇 |
2004年 | 2310篇 |
2003年 | 2189篇 |
2002年 | 2024篇 |
2001年 | 344篇 |
2000年 | 270篇 |
1999年 | 401篇 |
1998年 | 451篇 |
1997年 | 341篇 |
1996年 | 337篇 |
1995年 | 276篇 |
1994年 | 244篇 |
1993年 | 271篇 |
1992年 | 232篇 |
1991年 | 231篇 |
1990年 | 188篇 |
1989年 | 173篇 |
1988年 | 180篇 |
1987年 | 158篇 |
1986年 | 129篇 |
1985年 | 181篇 |
1984年 | 247篇 |
1983年 | 209篇 |
1982年 | 245篇 |
1981年 | 249篇 |
1980年 | 240篇 |
1979年 | 119篇 |
1978年 | 131篇 |
1977年 | 130篇 |
1976年 | 116篇 |
1974年 | 96篇 |
1973年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Gahan J Pandina Robert Bilder Philip D Harvey Richard S E Keefe Michael G Aman Georges Gharabawi 《Neuropsychopharmacology》2007,62(3):226-234
BACKGROUND: Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed. METHODS: Data from two 6-week, double-blind, placebo-controlled studies (n = 228) were combined, as were three 1-year, open-label studies (n = 688). Patients with DBDs and subaverage IQ, 5 to14 years, received placebo or risperidone .02 to .06 mg/kg/day. Cognitive measures included the Continuous Performance Task (CPT) and Verbal Learning Test for Children (VLT-C). Efficacy was assessed using the Nisonger Child Behavior Rating Form (NCBRF). Adverse events were collected via spontaneous report; sedation was assessed using visual analog scale. RESULTS: Improvements on the NCBRF Conduct Problem subscale were significantly greater for risperidone- versus placebo-treated patients (-15.8 vs. -6.4, p < .0001) in short-term studies; significant reductions were observed in long-term studies (-16.3, p < .0001). No overall decline and some significant improvement in attention (CPT) and memory (VLT-C) were noted regardless of treatment in short-term studies. VLT-C improved significantly (p < .0001) for both groups, with no difference between treatment groups. Improvements in memory (VLT-C) and attention (CPT) were noted in long-term studies. Somnolence/sedation did not affect cognitive function. CONCLUSIONS: Cognitive function was not altered by risperidone in short-term studies and was maintained or improved with one year of treatment in children with DBDs and subaverage IQ, potentially representing age-appropriate gains. 相似文献
23.
Alfred Philip James Lake BSc MBBS FFARCS ; Kathiravelpillai Puvanachandra MBBS DO FRCS FRCOphth 《Pain practice》2004,4(2):130-131
Abstract: Stellate ganglion block is commonly used to treat the sympathetically maintained pain which may occur in one‐third of patients with complex regional pain syndrome type 1. A complication that followed a single block and presented a diagnostic dilemma for the ophthalmologist is reported. 相似文献
24.
25.
26.
Betlach Charles J. Arnold John D. Frost R. Wayne Leese Philip T. Gonzalez Mario A. 《Pharmaceutical research》1987,4(5):409-411
The bioavailability of a new sustained-release potassium chloride (KC1) tablet, designed for once-a-day dosing, was compared to a KC1 elixir using urinary excretion data. The study utilized 25 male volunteers dosed in a crossover design in a dietary/activity-controlled environment. The regimens consisted of a total of 80 mEq of potassium in three equally divided doses of elixir every 6 hr and a single 80-mEq dose using four 20-mEq sustained-release (SR) tablets. The mean time to maximum rate of potassium urinary excretion was 2.2 hr for the first elixir dose and 5.5 hr after the SR tablet (P < 0.01), thereby supporting the prolonged-release properties of this formulation. After correction for baseline urinary potassium excretion, the mean total 24-hr urinary potassium excretion was 42.18 mEq for the elixir and 40.41 mEq for the SR tablet. The results indicate that the absorption pattern from the SR tablet is equal to three doses of KC1 elixir dosed 6 hr apart. 相似文献
27.
Philip J. Langlais PhD Mark L. Wardlow BS Hitoshi Yamamoto MD 《Pediatric neurology》1991,7(6):440-445
Cerebrospinal fluid (CSF) from 7 patients with infantile spasms (mean age: 6.7 months) was collected before and after treatment with adrenocorticotropic hormone (ACTH). The concentration of neurotransmitter metabolites was analyzed using high-performance liquid chromatography and compared to the metabolite concentration in the CSF from 7 age-matched controls (mean age: 6.1 months). Pretreatment levels of CSF 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid, 3-methoxy-4-hydroxyphenyl glycol (MHPG), and kynurenine were significantly lower in infantile spasm patients compared to controls. Following treatment, marked increases in 5-HIAA and decreases in kynurenine levels were observed in the CSF of the 5 infants whose seizures were eliminated or reduced by ACTH. In the 2 nonresponders 5-HIAA levels decreased. The level of MHPG was reduced slightly in 5 infants, including the 2 nonresponders, and was increased in 2 responders. CSF homovanillic acid levels increased in 4 infantile spasm infants and decreased in 3 following ACTH. These data demonstrate that the presence of seizures in infantile spasms is associated with a significant decrease in serotonergic activity and that elimination of seizures by ACTH is accompanied by increased serotonin turnover. The simultaneous increase of 5-HIAA and decrease of kynurenine, an alternate metabolite of tryptophan, suggests an underlying disturbance of tryptophan metabolism in infantile spasms. The possibility that elimination of seizures by ACTH may be related to decreased production of certain kynurenine metabolites, particularly quinolinic acid, is discussed. 相似文献
28.
Diarrhea is common after liver transplantation (LT). The true incidence of diarrhea in liver transplant recipients is unknown but possibly ranges from 10% to 43% based on a few published studies in other solid organ and bone marrow transplantation. Infectious etiologies, including cytomegalovirus (CMV), Clostridium difficile, and occasional atypical intestinal infections, are the most common causes. Diarrhea is also a frequent side effect of immunosuppressive medications. To variable extents, mycophenolate mofetil (MMF), cyclosporine A (CSA), tacrolimus, and sirolimus are all known to be associated with diarrhea. Rarely, graft-versus-host disease (GVHD), lymphoproliferative disorder, de novo inflammatory bowel disease (IBD), or colon cancer may present as diarrhea. Flare-up of preexisting IBD is also not uncommon after LT. However, the cause of acute diarrhea remains unidentified in 1 of 3 patients. This review summarizes the literature and provides recommendations on the management of acute diarrhea after LT. Although our focus is on LT, the etiology and management recommendations apply to most transplant recipients. 相似文献
29.
30.
Philip S Wells Josdalyne L Anderson Marc A Rodger Nancy Carson Rebecca L Grimwood Steve P Doucette 《Blood coagulation & fibrinolysis》2006,17(7):533-538
The substitution of leucine for valine at amino acid position 34 of the factor XIII gene is commonly referred to as FXIII Val34Leu polymorphism. The homozygous leucine/leucine genotype has been reported to confer protection against venous thromboembolism, but previous studies have not evaluated a population limited to those with idiopathic venous thromboembolism. The primary objective of the study was to determine whether the FXIII Val34Leu polymorphism is independently associated with the occurrence of idiopathic venous thromboembolism. We prospectively enrolled consecutive patients with at least one objectively confirmed idiopathic venous thromboembolism. Friends of cases were recruited as controls and matched to cases by sex, ethnicity, and age. All participants were tested for the FXIII Val34Leu polymorphism in addition to several well-known thrombophilias. Data from 309 cases and 306 controls were analyzed. The FXIII leucine/leucine genotype was present in 4.9% of cases and 6.5% of controls. An adjusted odds ratio of 0.59 (95% confidence interval, 0.25-1.38) was found for the recessive model and 0.69 (95% confidence interval, 0.46-1.02) for the dominant model. Our results do not support an independent association of the FXIII Val34Leu polymorphism with idiopathic venous thromboembolism in our Caucasian Canadian study population. 相似文献